CLINICAL TRIALS PROFILE FOR VELUSETRAG

Clinical Trials for Velusetrag

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01467726 ↗	Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects	Completed	Theravance Biopharma	Phase 1	This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
NCT01467726 ↗	Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects	Completed	Theravance Biopharma R & D, Inc.	Phase 1	This is a Phase 1, Randomized, Placebo-Controlled, Double-Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects.
NCT01718938 ↗	Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis	Completed	Alfa Wassermann S.p.A.	Phase 2	This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will assess three oral doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three periods of 1-week duration each, with a 1-week washout period between treatment periods, in subjects with diabetic or idiopathic gastroparesis. Study 0093 will evaluate the effect of velusetrag in subjects with diabetic or idiopathic gastroparesis by assessing changes in gastric emptying.
NCT01718938 ↗	Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis	Completed	Alfasigma S.p.A.	Phase 2	This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will assess three oral doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three periods of 1-week duration each, with a 1-week washout period between treatment periods, in subjects with diabetic or idiopathic gastroparesis. Study 0093 will evaluate the effect of velusetrag in subjects with diabetic or idiopathic gastroparesis by assessing changes in gastric emptying.

Clinical Trial Conditions for Velusetrag

Condition Name

Condition Name
Intervention	Trials
Gastroparesis	2
Alzheimer's Disease	1
Chronic Intestinal Pseudo-obstruction	1

Condition MeSH

Condition MeSH
Intervention	Trials
Gastroparesis	2
Intestinal Pseudo-Obstruction	1
Alzheimer Disease	1

Clinical Trial Locations for Velusetrag

Trials by Country

Trials by Country
Location	Trials
United States	35
Poland	3
Sweden	1
Spain	1
Italy	1

Trials by US State

Trials by US State
Location	Trials
Virginia	2
Oregon	2
North Carolina	2
Indiana	2
California	2

Clinical Trial Progress for Velusetrag

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	3
Phase 1	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	3
Active, not recruiting	1

Clinical Trial Sponsors for Velusetrag

Sponsor Name

Sponsor Name
Sponsor	Trials
Theravance Biopharma	3
Theravance Biopharma R & D, Inc.	3
Alfasigma S.p.A.	3

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	11